sulfatase modifying factor 1
Last updated 18 Aug 2020
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Ask Patient
- Audio Version
- Add to preferred sources on Google
The SUMF1 gene provides instructions for making an enzyme called formylglycine-generating enzyme (FGE). This enzyme is found in a cell structure called the endoplasmic reticulum, which is involved in protein processing and transport. The FGE enzyme modifies other enzymes called sulfatases, which aid in breaking down substances that contain chemical groups known as sulfates. These substances include a variety of sugars, fats, and hormones. Specifically, FGE converts a protein building block (amino acid) within sulfatases called cysteine into a molecule called C-alpha-formylglycine.
Video picks for GenesVideo library
Normal function
The SUMF1 gene provides instructions for making an enzyme called formylglycine-generating enzyme (FGE). This enzyme is found in a cell structure called the endoplasmic reticulum, which is involved in protein processing and transport. The FGE enzyme modifies other enzymes called sulfatases, which aid in breaking down substances that contain chemical groups known as sulfates. These substances include a variety of sugars, fats, and hormones. Specifically, FGE converts a protein building block (amino acid) within sulfatases called cysteine into a molecule called C-alpha-formylglycine.
Conditions referring to this gene or chromosome
Other names
AAPA3037
C-alpha-formylglycine-generating enzyme 1
FGE
FGly-generating enzyme
sulfatase-modifying factor 1
UNQ3037
Patient picks for Genes

Treatment and medication
Disease-modifying antirheumatic drugs
Disease-modifying antirheumatic drugs (DMARDs) are medicines that are normally prescribed as soon as rheumatoid arthritis (RA) is diagnosed, in order to reduce damage to the joints. Rarely, they can have serious side-effects affecting the blood, liver, or kidneys. DMARDS are usually taken for the rest of your life. Because they are taken for a long time you need to have regular blood tests, to see if the DMARDs are having any side-effects.
by Dr Colin Tidy, MRCGP

Heart health and blood vessels
Dilated cardiomyopathy causes: what are the risk factors?
Having dilated cardiomyopathy means that your heart muscle is weakened, which affects how your heart pumps blood around your body. There are a wide range of dilated cardiomyopathy causes, including genetics, other health conditions, alcohol consumption and a poor diet. While we can't control some of these risk factors, we can make positive lifestyle changes to reduce our risk of developing dilated cardiomyopathy.
by Amberley Davis

Cancer
Breast cancer facts and risk factors
Most cases of breast cancer occur by chance. However, breast cancer does occur more often than usual in some families because of their genetic makeup.
by Dr Colin Tidy, MRCGP

Treatment and medication
What factors are causing antimicrobial resistance?
Following a recent study by health economists at the University of Manchester and the University of Southern Denmark, the tremendous pressure GPs are currently working under has been linked to increasing broad-spectrum antibiotic prescribing in England. Because excess antibiotic prescribing has been closely linked to antibiotic resistance, there are concerns that these higher prescribing levels may be contributing to antimicrobial resistance.
by Emily Jane Bashforth

PID Q&A
Does PID cause bleeding?
Dr Sarah Jarvis MBE Symptoms may develop quickly. You can become quite ill over a few days. Sometimes symptoms are mild and develop slowly. For example, you may just have a mild abdominal pain that may 'grumble on' for weeks. In some cases no symptoms develop and you do not know that you are infected. However, you are still at risk of complications even if you have no symptoms at first. [https://patient.info/health/pelvic-pain-in-women/pelvic-inflammatory-disease#nav-1](https://patient.info/health/pelvic-pain-in-women/pelvic-inflammatory-disease#nav-1)
by Dr Sarah Jarvis

PID Q&A
How do you diagnose PID?
Dr Sarah Jarvis MBE Symptoms may develop quickly. You can become quite ill over a few days. Sometimes symptoms are mild and develop slowly. For example, you may just have a mild abdominal pain that may 'grumble on' for weeks. In some cases no symptoms develop and you do not know that you are infected. However, you are still at risk of complications even if you have no symptoms at first. [https://patient.info/health/pelvic-pain-in-women/pelvic-inflammatory-disease#nav-1](https://patient.info/health/pelvic-pain-in-women/pelvic-inflammatory-disease#nav-1)
by Dr Sarah Jarvis
Related patient information and medicines

Patient information leaflet
Disease-modifying antirheumatic drugs
Disease-modifying antirheumatic drugs (DMARDs) are medicines that are normally prescribed as soon as rheumatoid arthritis (RA) is diagnosed, in order to reduce damage to the joints. Disease-modifying antirheumatic drugs (DMARDs) are a group of medicines that are used to ease the symptoms of rheumatoid arthritis (RA) Rheumatoid arthritis and reduce.

Patient information leaflet
Reactive arthritis
... If symptoms continue for more than a few months, or if other treatments have not worked, you may be advised to take a disease-modifying medicine Disease-modifying antirheumatic drugs. These are sometimes called disease-modifying antirheumatic drugs (DMARDs). This aims to reduce the damaging effect on the joints. There are several - for.

Patient information leaflet
Psoriatic arthritis
Psoriatic arthritis is a particular type of arthritis that develops in some people who also have psoriasis. Arthritis Arthritis means inflammation of the joints. They work by blocking the effects of chemicals involved in causing joint inflammation. Sulfasalazine Sulfasalazine and methotrexate Methotrexate are the most commonly used DMARDs for.

Patient information leaflet
Rheumatoid arthritis
Rheumatoid arthritis causes inflammation, pain, and swelling of joints. Rheumatoid arthritis treatment Standards of care you should expect The National Institute for Health and Care Excellence (NICE) has published quality standards on the standard of care that should be offered to every adult over 16 who has RA. ...Ds) Disease-modifyingDMARDs.

Patient information leaflet
Primary sclerosing cholangitis
Primary sclerosing cholangitis is an uncommon condition affecting the bile ducts and liver. Inflammation and scarring of the bile ducts can lead to liver damage and cirrhosis - a condition where normal liver tissue is replaced by scar tissue (fibrosis). Different treatments are available to control symptoms that may develop and also to manage ....

Patient information leaflet
Juvenile idiopathic arthritis
So, juvenile idiopathic arthritis (JIA) is a condition in which this inflammation of one or more joints begins in children under the age of 16 years. ...e used to help reduce the effects of the disease Disease-modifyingDMARDs used for JIA include: Methotrexate Methotrexate Sulfasalazine Sulfasalazine Leflunomide Leflunomide tablets for arthritis.
Further reading and references
- sulfatase modifying factor 1; MedlinePlus, National Library of Medicine.
- Annunziata I, Bouche V, Lombardi A, Settembre C, Ballabio A. Multiple sulfatase deficiency is due to hypomorphic mutations of the SUMF1 gene. Hum Mutat. 2007 Sep;28(9):928. doi: 10.1002/humu.9504.
- Cosma MP, Pepe S, Annunziata I, Newbold RF, Grompe M, Parenti G, Ballabio A. The multiple sulfatase deficiency gene encodes an essential and limiting factor for the activity of sulfatases. Cell. 2003 May 16;113(4):445-56. doi: 10.1016/s0092-8674(03)00348-9.
- Cosma MP, Pepe S, Parenti G, Settembre C, Annunziata I, Wade-Martins R, Di Domenico C, Di Natale P, Mankad A, Cox B, Uziel G, Mancini GM, Zammarchi E, Donati MA, Kleijer WJ, Filocamo M, Carrozzo R, Carella M, Ballabio A. Molecular and functional analysis of SUMF1 mutations in multiple sulfatase deficiency. Hum Mutat. 2004 Jun;23(6):576-81. doi: 10.1002/humu.20040.
- Dierks T, Dickmanns A, Preusser-Kunze A, Schmidt B, Mariappan M, von Figura K, Ficner R, Rudolph MG. Molecular basis for multiple sulfatase deficiency and mechanism for formylglycine generation of the human formylglycine-generating enzyme. Cell. 2005 May 20;121(4):541-552. doi: 10.1016/j.cell.2005.03.001.
- Dierks T, Schmidt B, Borissenko LV, Peng J, Preusser A, Mariappan M, von Figura K. Multiple sulfatase deficiency is caused by mutations in the gene encoding the human C(alpha)-formylglycine generating enzyme. Cell. 2003 May 16;113(4):435-44. doi: 10.1016/s0092-8674(03)00347-7.
- Schlotawa L, Ennemann EC, Radhakrishnan K, Schmidt B, Chakrapani A, Christen HJ, Moser H, Steinmann B, Dierks T, Gartner J. SUMF1 mutations affecting stability and activity of formylglycine generating enzyme predict clinical outcome in multiple sulfatase deficiency. Eur J Hum Genet. 2011 Mar;19(3):253-61. doi: 10.1038/ejhg.2010.219. Epub 2011 Jan 12.
- Schlotawa L, Radhakrishnan K, Baumgartner M, Schmid R, Schmidt B, Dierks T, Gartner J. Rapid degradation of an active formylglycine generating enzyme variant leads to a late infantile severe form of multiple sulfatase deficiency. Eur J Hum Genet. 2013 Sep;21(9):1020-3. doi: 10.1038/ejhg.2012.291. Epub 2013 Jan 16.
- Schlotawa L, Steinfeld R, von Figura K, Dierks T, Gartner J. Molecular analysis of SUMF1 mutations: stability and residual activity of mutant formylglycine-generating enzyme determine disease severity in multiple sulfatase deficiency. Hum Mutat. 2008 Jan;29(1):205. doi: 10.1002/humu.9515.
Share your thoughts or experiences with others in our patient communities.
Sign up to the Patient newsletter
Your weekly dose of clear, trustworthy health advice - written to help you feel informed, confident and in control.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.

